Vertex Pharmaceuticals, Inc. (VRTX)
544.74
+3.05
(+0.56%)
USD |
NASDAQ |
Aug 31, 16:00
545.00
+0.26
(+0.05%)
After-Hours: 20:00
Vertex Pharmaceuticals Cash from Operations (TTM) : 4.293B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.293B |
| March 31, 2026 | 4.241B |
| December 31, 2025 | 3.631B |
| September 30, 2025 | 3.718B |
| June 30, 2025 | 3.846B |
| March 31, 2025 | -980.30M |
| December 31, 2024 | -492.60M |
| September 30, 2024 | -842.60M |
| June 30, 2024 | -944.00M |
| March 31, 2024 | 3.944B |
| December 31, 2023 | 3.537B |
| September 30, 2023 | 4.381B |
| June 30, 2023 | 4.068B |
| March 31, 2023 | 4.074B |
| December 31, 2022 | 4.130B |
| September 30, 2022 | 4.046B |
| June 30, 2022 | 4.018B |
| March 31, 2022 | 2.679B |
| December 31, 2021 | 2.644B |
| September 30, 2021 | 2.140B |
| June 30, 2021 | 2.121B |
| March 31, 2021 | 3.359B |
| December 31, 2020 | 3.254B |
| September 30, 2020 | 3.208B |
| June 30, 2020 | 2.635B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.060B |
| December 31, 2019 | 1.569B |
| September 30, 2019 | 1.438B |
| June 30, 2019 | 1.484B |
| March 31, 2019 | 1.342B |
| December 31, 2018 | 1.270B |
| September 30, 2018 | 1.183B |
| June 30, 2018 | 971.96M |
| March 31, 2018 | 831.91M |
| December 31, 2017 | 844.94M |
| September 30, 2017 | 762.16M |
| June 30, 2017 | 657.72M |
| March 31, 2017 | 516.93M |
| December 31, 2016 | 236.10M |
| September 30, 2016 | 75.36M |
| June 30, 2016 | -37.32M |
| March 31, 2016 | -173.39M |
| December 31, 2015 | -365.43M |
| September 30, 2015 | -471.29M |
| June 30, 2015 | -511.91M |
| March 31, 2015 | -544.62M |
| December 31, 2014 | -513.20M |
| September 30, 2014 | -362.47M |
| June 30, 2014 | -288.55M |
| March 31, 2014 | -161.55M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Gilead Sciences, Inc. | 13.55B |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Sionna Therapeutics, Inc. | -75.92M |
| Regeneron Pharmaceuticals, Inc. | 4.681B |
| Biogen, Inc. | 2.879B |